Deep-pocketed investors have adopted a bullish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRNA usually suggests something big is about to happen.We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Moderna. ...

Outrage in the medical community as the vaccine overhaul under the Trump administration continues. A CDC vaccine advisory panel has rolled back a decadesl long recommendation that all newborns get a first dose of the hepatitis B vaccine within 24 hours of birth. Now, that recommendation is specifically for babies born to mothers who test negative for the virus.And here's what the president of the American Academy of Pediatrics had to say. were exhausted, despondent, and angry because we know behind all of t ...

Your administration speaks a lot about gold standard science. What is gold standard science to you? >> It's science itself. Science means that you can question everything. >> You spoke about listening to the science. Today, the CDC's vaccine committee is considering changing the HEP schedule. And yet we have 30 years of experience that says that giving an newborn dose of HEP B dramatically reduces the cases of HEP B infants. It's practically been eliminated. Why? As a doctor, what do you think about that? W ...

In a New England Journal of Medicine Oped, 12 former FDA commissioners are sounding the alarm on FDA vaccine coordinator Dr. . Venet Prasad's imposing of sweeping changes to how the US handles vaccinations. Joining us now, a former FDA commissioner and CNBC contributor Dr.. Scott Gotautle. He's on the boards of Aluminina, Fizer, and United Health. He's also one of the co-authors of the OpEd.And doctor, just get get it out of the way. I people are going to say, "Oh, yeah, gee, a Fiser guy is is promoting vac ...

Vaccine Safety Concerns - An FDA memo claimed 10 children died after receiving the COVID vaccine between 2021 and 2024, based on reports to the Vaccine Adverse Event Reporting System [1] - The FDA's claims lack supporting evidence such as autopsy data, infection status, or detailed case reports [4][5] - Experts criticize the FDA's approach as unprofessional and irresponsible for not publishing findings in a peer-reviewed journal [5][6] Myocarditis and Vaccine Link - Myocarditis, or inflammation of the heart muscle, can be caused by the SARS-CoV-2 virus [8] - The COVID vaccine has been linked to mild myocarditis in some individuals, primarily 16-29 year old males, after the second dose [8] - The FDA is claiming the vaccine caused severe and fatal myocarditis in some children, but needs to provide evidence [8][9] Changes in Vaccine Review Process and Trust in Authorities - The director of the FDA's vaccine division has proposed new changes to the vaccine review process [9] - Concerns arise regarding the CDC's Advisory Committee for Immunization Practices (ACIP) due to the appointment of individuals with anti-vaccine views [10][11] - The medical and scientific community expresses distrust in the ACIP and CDC for providing valid information and advice [12] Alternative Information Sources - Professional societies and centers are working to provide evidence-based information and good medical practices regarding vaccines [13]

The FDA claiming without evidence that CO shots are linked to at least 10 children's deaths and vowing new vaccine rules because of it. In an internal memo obtained by NBC News, the director of the FDA's vaccine division, Dr. . Venet Prasad, alleges no fewer than 10 deaths reported to the agency between 2021 and 2024 were related to the COVID vaccine.The memo did not include the children's ages or medical history, did not identify the vaccine manufacturer, and these findings have not been published in a pee ...

Tonight, the FDA claiming without evidence that CO shots are linked to at least 10 children's deaths and vowing new vaccine rules because of it. In an internal memo obtained by NBC News, the director of the FDA's vaccine division, Dr. . Venet Prasad, alleges no fewer than 10 deaths reported to the agency between 2021 and 2024 were related to the COVID vaccine.>> It appears 10 deaths of children from the COVID shot. We're going to make that information available uh that those cases were reviewed. >> The memo ...

Core Insights - Novavax has shifted its strategic focus and aims to leverage its unique technology to differentiate itself in the market [1] Company Overview - Novavax is recognized for developing a highly effective COVID vaccine during the pandemic, a feat not achieved by many larger pharmaceutical companies [1] - The company's success is attributed to its core technology, which utilizes subunit protein nano-based technology for antigen creation, combined with the effective adjuvant Matrix-M [1][2]

Core Insights - Pfizer Inc announced plans to sell 54.7% of its stake in German drugmaker BioNTech SE, marking a significant shift in their partnership established over five years ago that resulted in a vaccine to combat a deadly virus [1] Company Summary - Pfizer Inc is divesting a majority of its stake in BioNTech SE, indicating a strategic move away from their previous collaboration [1] - The alliance between Pfizer and BioNTech was pivotal in developing a vaccine, showcasing the importance of their partnership in addressing public health challenges [1] Industry Summary - The sale of Pfizer's stake in BioNTech may reflect broader trends in the pharmaceutical industry regarding partnerships and investments in vaccine development [1] - This decision could influence market dynamics and investor sentiment towards companies involved in vaccine production and public health initiatives [1]

Group 1: Q3 Earnings Overview - The Q3 earnings season has started positively, with 91% of S&P 500 companies reporting results, and analysts expect a 13.1% increase in earnings per share, marking the fourth consecutive quarter of double-digit growth [2][9] - Initial expectations were lower, with analysts predicting a 7.9% increase in earnings per share as of September 30 [3] - Companies have reported more positive earnings surprises (82%) than negative ones (18%), with 77% of companies also reporting positive revenue surprises [9] Group 2: Notable Company Earnings - Instacart reported GAAP earnings per share of $0.51, exceeding estimates of $0.50, with revenue of $939 million, surpassing expectations of $933 million [6] - Constellation Energy's stock fell nearly 6% after reporting GAAP earnings per share of $2.97, missing estimates of $3.05, although revenue of $6.57 billion exceeded expectations [12] - Wendy's reported revenue of $549 million, a 3% decline year-over-year but above estimates of $534 million, with earnings per share of $0.24 beating expectations of $0.20 [16][17] - Block's shares fell 15% after reporting earnings per share of $0.54 on revenue of $6.11 billion, missing estimates of $0.68 per share and $6.31 billion in revenue [23] - Airbnb's stock rose 5% as it reported 133.6 million nights booked, a 9% increase year-over-year, driven by international bookings [32][33] Group 3: Industry Trends and Challenges - The earnings growth rate for Q3 is on track to increase from Q2, driven by tech enthusiasm around artificial intelligence and ongoing tariff concerns [10] - Consumer-facing companies are experiencing pressures from affordability and sentiment, with mentions of government shutdown impacts increasing [11] - Under Armour reported a net loss of $0.04 per share, with revenue declining 4.7% year-over-year, attributed to challenging consumer demand [35][36]